Company
Skye Bioscience, Inc.
Unlocking new therapeutic pathways for metabolic health
- Business model
- B2B
- Legal name
- Skye Bioscience, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
We are a biotechnology company developing next-generation drugs to treat obesity and other metabolic diseases. Our focus is on advancing first-in-class molecules that modulate G-protein coupled receptors with the potential to provide enhanced health outcomes for diseases with significant prevalence and unmet needs.
Funding snapshot
- Total raised
- $168MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $40M2024-03-13
Funding rounds
- Round, 2024
- $40M2024-03-13, SEC form D sold, 13 investors
- Round, 2024
- $50M2024-01-31, SEC form D sold, 11 investors
- Round, 2023
- $62.3M2023-08-15, SEC form D sold, 12 investors
- Round, 2018
- $2M2018-11-01, SEC form D sold, 1 investor
- Round, 2018
- $4.2M2018-01-18, SEC form D sold, 2 investors
- Round, 2017
- $2M2017-11-01, SEC form D sold, 2 investors
- Round, 2017
- $1.2M2017-01-03, SEC form D sold, 5 investors
- Round, 2016
- $500K2016-10-26, SEC form D sold, 1 investor
- Round, 2015
- $5M2015-08-20, SEC form D sold, 15 investors
- Round, 2015
- $625K2015-04-01, SEC form D sold, 5 investors
- Round, 2015
- $725K2015-01-07, SEC form D sold, 7 investors
- Round, 2014
- 2014-10-3143 investors
- Round, 2012
- $24.8K2012-11-08, SEC form D sold, 13 investors
- Round, 2011
- $9K2011-03-25, SEC form D sold, 7 investors
Products
- Web
- Nimacimab
Loading relationship preview